Plasma Energy Loss into Kaluza-Klein Modes

Recently, Barger {\em et al.} computed energy losses into Kaluza Klein modes from astrophysical plasmas in the approximation of zero density for the plasmas. We extend their work by considering the effects of finite density for two plasmon processes. Our results show that, for fixed temperature, the energy loss rate per cm$^3$ is constant up to some critical density and then falls exponentially. This is true for transverse and longitudinal plasmons in both the direct and crossed channels over a wide range of temperature and density. A difficulty in deriving the appropriate covariant interaction energy at finite density and temperature is addressed. We find that, for the cases considered by Barger {\em et al.}, the zero density approximation and the neglect of other plasmon processes is justified to better than an order of magnitude.Comment: 17 pages, LaTeX2e, 4 figures, 11 table

Cerenkov radiation of longitudinal photons by neutrinos

In a relativistic plasma neutrino can emit plasmons by the Cerenkov process which is kinematically allowed for a range of frequencies for which refractive index is greater than one. We have calculated the rate of energy emission by this process. We compute the energy deposited in a stalled supernova shock wave by the Cerenkov process and find that it is much smaller than the Bethe-Wilson mechanism.Comment: 11 pages, 2 figures available on reques

COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing

Background Lateral flow device (LFD) viral antigen immunoassays have been developed around the world as diagnostic tests for SARS-CoV-2 infection. They have been proposed to deliver an infrastructure-light, cost-economical solution giving results within half an hour. Methods LFDs were initially reviewed by a Department of Health and Social Care team, part of the UK government, from which 64 were selected for further evaluation from 1st August to 15th December 2020. Standardised laboratory evaluations, and for those that met the published criteria, field testing in the Falcon-C19 research study and UK pilots were performed (UK COVID-19 testing centres, hospital, schools, armed forces). Findings 4/64 LFDs so far have desirable performance characteristics (orient Gene, Deepblue, Abbott and Innova SARS-CoV-2 Antigen Rapid Qualitative Test). All these LFDs have a viral antigen detection of >90% at 100,000 RNA copies/ml. 8951 Innova LFD tests were performed with a kit failure rate of 5.6% (502/8951, 95% CI: 5.1–6.1), false positive rate of 0.32% (22/6954, 95% CI: 0.20–0.48). Viral antigen detection/sensitivity across the sampling cohort when performed by laboratory scientists was 78.8% (156/198, 95% CI 72.4–84.3). Interpretation Our results suggest LFDs have promising performance characteristics for mass population testing and can be used to identify infectious positive individuals. The Innova LFD shows good viral antigen detection/sensitivity with excellent specificity, although kit failure rates and the impact of training are potential issues. These results support the expanded evaluation of LFDs, and assessment of greater access to testing on COVID-19 transmission. Funding Department of Health and Social Care. University of Oxford. Public Health England Porton Down, Manchester University NHS Foundation Trust, National Institute of Health Research